• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨肉瘤治疗后心肌病:阿霉素心脏毒性的一项研究

[Cardiomyopathy after osteosarcoma treatment: a contribution to the cardiotoxicity of adriamycin].

作者信息

Geidel S, Garn M, Grävinghoff L, Hausdorf G, Morf G, Bielack S, Knop J, Winkler K

机构信息

Kinderklinik der Universität Hamburg.

出版信息

Klin Padiatr. 1991 Jul-Aug;203(4):257-61. doi: 10.1055/s-2007-1025438.

DOI:10.1055/s-2007-1025438
PMID:1942931
Abstract

The frequency and severity of clinical and subclinical heart damage were studied in patients who had been treated with adriamycin (ADR) as part of the Cooperative Osteosarcoma Studies (COSS). The study charts of 785 patients from 63 participating institutions were reviewed: The overall incidence of drug-induced congestive heart failure was 2.2% (17 cases, 5 fatal). Late left ventricular function was studied in 29 tumor free survivors 81 +/- 41 month after treatment with 342 +/- 113 mg/m2 ADR. A detailed history and physical exam for signs of overt heart disease were obtained. M-mode echocardiography (ECHO, 29 cases) with evaluation of the fractional shortening rate (FS) and radionuclide ventriculography (RNV, 18 cases) with determination of the systolic ejection fraction at rest (EF) were used to screen for subclinical cardiac disease. Impaired cardiac function leading to pathological values was documented in close to one half of these patients. The frequency and severity of clinical and subclinical heart damage increased with cumulative adriamycin and time since cessation of anthracycline therapy.

摘要

在作为骨肉瘤协作研究(COSS)一部分接受阿霉素(ADR)治疗的患者中,对临床和亚临床心脏损伤的频率及严重程度进行了研究。回顾了来自63个参与机构的785例患者的研究图表:药物性充血性心力衰竭的总体发生率为2.2%(17例,5例死亡)。在29例无肿瘤存活者中,于接受342±113mg/m²阿霉素治疗后81±41个月研究晚期左心室功能。获取了关于明显心脏病体征的详细病史和体格检查结果。采用评估缩短分数(FS)的M型超声心动图(ECHO,29例)和测定静息时收缩射血分数(EF)的放射性核素心室造影(RNV,18例)来筛查亚临床心脏疾病。近一半的这些患者记录到导致病理值的心脏功能受损。临床和亚临床心脏损伤的频率及严重程度随阿霉素累积剂量和蒽环类药物治疗停止后的时间而增加。

相似文献

1
[Cardiomyopathy after osteosarcoma treatment: a contribution to the cardiotoxicity of adriamycin].骨肉瘤治疗后心肌病:阿霉素心脏毒性的一项研究
Klin Padiatr. 1991 Jul-Aug;203(4):257-61. doi: 10.1055/s-2007-1025438.
2
Long-term follow-up of patients with doxorubicin-induced cardiac toxicity after chemotherapy for osteosarcoma.骨肉瘤化疗后多柔比星诱导的心脏毒性患者的长期随访
Anticancer Drugs. 2007 Jul;18(6):737-44. doi: 10.1097/CAD.0b013e32803d36fe.
3
Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults.成人淋巴瘤患者接受阿霉素治疗后出现的亚临床晚期心肌病。
J Clin Oncol. 2004 May 15;22(10):1864-71. doi: 10.1200/JCO.2004.06.033.
4
Prospective longitudinal evaluation of doxorubicin-induced cardiomyopathy in sarcoma patients: a report of the late effects surveillance system (LESS).肉瘤患者中多柔比星诱导的心肌病的前瞻性纵向评估:晚期效应监测系统(LESS)报告
Pediatr Blood Cancer. 2006 Apr;46(4):489-95. doi: 10.1002/pbc.20492.
5
Limited cardiotoxicity after extensive thoracic surgery and intraoperative hyperthermic intrathoracic chemotherapy with doxorubicin and cisplatin.广泛胸科手术后联合术中使用阿霉素和顺铂进行胸内高温化疗后的心脏毒性有限。
Ann Surg Oncol. 2007 Oct;14(10):3019-26. doi: 10.1245/s10434-007-9508-3. Epub 2007 Jul 20.
6
Cardiac troponin I: is it a marker to detect cardiotoxicity in children treated with doxorubicin?心肌肌钙蛋白I:它是检测接受多柔比星治疗儿童心脏毒性的标志物吗?
Turk J Pediatr. 2005 Jan-Mar;47(1):17-22.
7
Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.吡柔比星联合5-氟尿嘧啶和环磷酰胺治疗转移性乳腺癌的II期临床与药理学研究
Clin Cancer Res. 1995 Jul;1(7):691-7.
8
[Echocardiography with angiotensin administration in the diagnosis of adriamycin-induced cardiomyopathy].[血管紧张素给药超声心动图在阿霉素诱导的心肌病诊断中的应用]
Z Kardiol. 1989 May;78(5):320-7.
9
Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials.骨肉瘤化疗的剂量强度与骨肉瘤协作研究组(COSS)试验的结果
Pediatr Blood Cancer. 2006 Jul;47(1):42-50. doi: 10.1002/pbc.20608.
10
[Neoadjuvant chemotherapy of osteosarcoma. Results of the cooperative studies COSS-80 and COSS-82 after 7 and 5 years].骨肉瘤的新辅助化疗。7年和5年后COSS - 80及COSS - 82合作研究结果
Klin Padiatr. 1989 Jul-Aug;201(4):275-84. doi: 10.1055/s-2008-1026715.

引用本文的文献

1
Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies.靶向骨肉瘤治疗效果和耐药性的分子机制:当前和未来策略的综述。
Int J Mol Sci. 2020 Sep 19;21(18):6885. doi: 10.3390/ijms21186885.
2
Livin and Bcl-2 expression in high-grade osteosarcoma.Livin和Bcl-2在高级别骨肉瘤中的表达
J Cancer Res Clin Oncol. 2008 Feb;134(2):237-44. doi: 10.1007/s00432-007-0276-z. Epub 2007 Jul 14.